Gameto, a female-led biotech company aiming to revolutionize the female reproductive journey, is pleased to announce the addition of Teri Loxam as its inaugural Chief Financial Officer. In this new role, Teri will be responsible for driving Gameto’s financial strategy and helping to shape the company’s overall direction. Her extensive experience in the biotech industry makes her a perfect fit for this position and will be a great asset to the team.
Teri’s decades of experience in financial management, capital markets, and biotechnology and pharmaceutical industries make her an invaluable asset to Gameto as we move forward with our clinical development and go-to-market strategy for Fertilo.
Her impressive leadership skills and personal passion for women’s health will be a great addition to our team as we continue to grow. With Teri on board, Gameto will be well-equipped to make the IVF process shorter, safer and more effective for women.
Teri brings over two decades of experience in strategy, investor relations, and finance to Gameto, having worked across the pharmaceutical, biotech, and TMT industries. Most recently, she served as Chief Operating Officer and Chief Financial Officer of Kira Pharmaceuticals, where she built financial and operational functions across U.S. and China locations to get the company ready for public listing.
Prior to Kira, Teri was CFO of SQZ Biotechnologies, raising over $200 million and taking the company public in October 2020. Additionally, Teri has held various positions at Merck, IMAX Corporation, and Bristol-Myers Squibb.
Teri is an inspiring leader and board member, currently serving as the audit chair of Vaxcyte, Inc. and Cardiol Therapeutics, Inc. She earned a B.S. in Biology from the University of Victoria, B.C. Canada and an MBA from the University of California, Irvine. With these impressive credentials, Teri is helping to shape the future of the healthcare industry with her passion and expertise.
Teri Loxam, Chief Financial Officer of Gameto, is thrilled to join a team of passionate professionals who are revolutionizing the traditional IVF processes and making great strides in advancing women’s health. She is impressed by Gameto’s platform and its dedication to continuously improve and support women’s wellbeing.
Gameto recently welcomed Jean-Pierre Gotteland to its management team as Head of Development. He has a wealth of experience in the pharmaceutical industry, having formerly served as Chief Scientific Officer and Head of R&D at ObsEva SA.
There, he saw the development and approval of linzagolix for uterine fibroids, as well as the clinical trials of nolasiban to increase live birth rate after IVF. He was also Chief Development Officer at PregLem SA, where he oversaw the EU approval of ulipristal acetate for uterine fibroids and infertility.
Before this, Jean-Pierre had many R&D roles at Serono, which was later acquired by Merck KgA. Teri’s appointment was one of many senior hires this year, making it an exciting time for Gameto.
Jean-Pierre will be spearheading the clinical development progress of Gameto’s revolutionary lead program, Fertilo. This new team of experts composed of stem cell engineers, computational biologists, embryologists and physicians has been assembled to help Gameto unlock the potential of this breakthrough program. With Jean-Pierre at the helm, this multidisciplinary team is ready to push the envelope in fertility treatments.
Gameto is a biotechnology company on a mission to revolutionize the female reproductive journey. Based in New York and Madrid, they are developing innovative therapeutics to improve the process of IVF and egg freezing. Their first product, Fertilo, has been clinically tested with partners Inception Fertility, Spring Fertility, Extend Fertility, RMA, Pozitivf, Ovation Fertility, ReproART, Clinica Tambre, and Hospital Ruber Internacional, Eugin Group.
The preclinical studies found that Fertilo can increase egg yield per cycle and maturation for both conventional and reduced stimulation cycles – making the process shorter, safer and more effective. Gameto is committed to providing women with the support they need throughout their reproductive journey.
At the helm of Gameto is physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and leader in the fertility space Martin Varsavsky as Chairman. Together, this dynamic duo is leading the way in revolutionizing the fertility space with their innovative approach.